{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:30:33Z","timestamp":1787668233015,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05453-z","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:18:19Z","timestamp":1779427099000},"page":"17317-17342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study"],"prefix":"10.1007","volume":"399","author":[{"given":"Ying","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Li","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"5453_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S (2020) Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf 11:2042098620938595","journal-title":"Ther Adv Drug Saf"},{"issue":"9","key":"5453_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"S Apostolakis","year":"2012","unstructured":"Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY (2012) Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 60(9):861\u2013867","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"5453_CR3","volume":"3","author":"KM Bruins Slot","year":"2018","unstructured":"Bruins Slot KM, Berge E (2018) Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 3(3):Cd008980","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"5453_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41371-022-00690-0","volume":"37","author":"NRC Campbell","year":"2023","unstructured":"Campbell NRC, Whelton PK, Orias M, Wainford RD, Cappuccio FP, Ide N et al (2023) 2022 World hypertension league, resolve to save lives and international society of hypertension dietary sodium (salt) global call to action. J Hum Hypertens 37(6):428\u2013437","journal-title":"J Hum Hypertens"},{"issue":"7","key":"5453_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.7326\/M20-6194","volume":"174","author":"GK Dawwas","year":"2021","unstructured":"Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD (2021) Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation\u202f: a population-based cohort study. Ann Intern Med 174(7):910\u2013919","journal-title":"Ann Intern Med"},{"issue":"2","key":"5453_CR6","first-page":"108173","volume":"34","author":"L di Biase","year":"2025","unstructured":"di Biase L, Bonura A, Pecoraro PM, Di Lazzaro V (2025) Real-world safety profile of direct oral anticoagulants (DOACs): disproportionality analysis of major bleeding events. J Nat Stroke Assoc 34(2):108173","journal-title":"J Nat Stroke Assoc"},{"key":"5453_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.hjc.2023.04.004","volume":"73","author":"K Dimitriadis","year":"2023","unstructured":"Dimitriadis K, Soulaidopoulos S, Doundoulakis I, Iliakis P, Tsiachris D, Tsioufis P et al (2023) A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: focus on bleeding. Hellenic J Cardiol 73:69\u201372","journal-title":"Hellenic J Cardiol"},{"issue":"4","key":"5453_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.14398","volume":"17","author":"MAT Elsebaie","year":"2019","unstructured":"Elsebaie MAT, van Es N, Langston A, B\u00fcller HR, Gaddh M (2019) Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thrombos Haemos JTH 17(4):645\u2013656","journal-title":"J Thrombos Haemos JTH"},{"issue":"11","key":"5453_CR9","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/pds.4034","volume":"25","author":"A Gorst-Rasmussen","year":"2016","unstructured":"Gorst-Rasmussen A, Lip GY, Bjerregaard LT (2016) Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 25(11):1236\u20131244","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5453_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/VHRM.S121661","volume":"13","author":"EL Hellenbart","year":"2017","unstructured":"Hellenbart EL, Faulkenberg KD, Finks SW (2017) Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 13:325\u2013342","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"5453_CR11","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al (2019) 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation 140(2):e125\u2013e151","journal-title":"Circulation"},{"issue":"15","key":"5453_CR12","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.7150\/ijms.122194","volume":"22","author":"LY Jin","year":"2025","unstructured":"Jin LY, Chen GQ, Xie J, Chen P, Sun HY, Zheng HL et al (2025) Real-world safety of anti-EGFR antibodies: 20-year pharmacovigilance of cetuximab and panitumumab. Int J Med Sci 22(15):4131\u20134144","journal-title":"Int J Med Sci"},{"key":"5453_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1133662","volume":"10","author":"LC Li","year":"2024","unstructured":"Li LC, Sun W, Lv XQ, Xu YY, Hu Y, Shi JN (2024) Escitalopram-induced sinus bradycardia in coronary heart disease combined with depression: a case report and review of literature. Front Cardiovasc Med 10:1133662","journal-title":"Front Cardiovasc Med"},{"key":"5453_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1512784","volume":"12","author":"LC Li","year":"2025","unstructured":"Li LC, Zhang S, Sun JB, Xu YY, Mao KL (2025) Case report: practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pharmacist\u2019s role. Front Cardiovasc Med 12:1512784","journal-title":"Front Cardiovasc Med"},{"key":"5453_CR15","doi-asserted-by":"crossref","unstructured":"Li LC, Zhang ZH, Chen MM, Xu F, Mao KL (2026) Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of FDA adverse event reporting system database and Japanese adverse drug event report database, and the role of pharmacists. Int J Surg 112(2):3612\u20133624","DOI":"10.1097\/JS9.0000000000003667"},{"issue":"7","key":"5453_CR16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.clinthera.2023.04.006","volume":"45","author":"TY Liu","year":"2023","unstructured":"Liu TY, Hsu HY, You YS, Hsieh YW, Lin TC, Peng CW et al (2023) Efficacy of warfarin therapy guided by pharmacogenetics: a real-world investigation among Han Taiwanese. Clin Ther 45(7):662\u2013670","journal-title":"Clin Ther"},{"key":"5453_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008643","author":"BK Martinez","year":"2018","unstructured":"Martinez BK, Sood NA, Bunz TJ, Coleman CI (2018) Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.118.008643","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"5453_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","volume":"134","author":"KT Mills","year":"2016","unstructured":"Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K et al (2016) Global disparities of hypertension prevalence and control. Circulation 134(6):441\u2013450","journal-title":"Circulation"},{"issue":"7","key":"5453_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","volume":"25","author":"R Morris","year":"2024","unstructured":"Morris R, Ali R, Cheng F (2024) Drug repurposing using FDA adverse event reporting system (FAERS) database. Curr Drug Targets 25(7):454\u2013464","journal-title":"Curr Drug Targets"},{"issue":"9","key":"5453_CR20","first-page":"e92760","volume":"17","author":"A Osman","year":"2025","unstructured":"Osman A, Kanaan A, Azeroual S, Abubakr M, Jwayyed J, Bhutta R (2025) Hypertension and cerebral small vessel disease: a review of the pathophysiology, progression, and prevention. Cureus 17(9):e92760","journal-title":"Cureus"},{"issue":"1_suppl","key":"5453_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/23969873231208544","volume":"10","author":"AR Parry-Jones","year":"2025","unstructured":"Parry-Jones AR, Moullaali TJ, Sandset EC, Qureshi AI, Anderson CS, Steiner T (2025) Importance of blood pressure lowering in patients with direct oral anticoagulant-associated intracerebral haemorrhage in the acute phase and for secondary prevention. Eur Stroke J 10(1_suppl):46\u201355","journal-title":"Eur Stroke J"},{"issue":"5","key":"5453_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093\u20131100","journal-title":"Chest"},{"issue":"9921","key":"5453_CR23","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962","journal-title":"Lancet"},{"issue":"7","key":"5453_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803","journal-title":"Int J Med Sci"},{"issue":"5","key":"5453_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda T, Kadoyama K, Minami K, Okuno Y (2014) Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci 11(5):461\u2013465","journal-title":"Int J Med Sci"},{"key":"5453_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jbi.2015.02.004","volume":"54","author":"A Sarker","year":"2015","unstructured":"Sarker A, Ginn R, Nikfarjam A, O\u2019Connor K, Smith K, Jayaraman S et al (2015) Utilizing social media data for pharmacovigilance: a review. J Biomed Inform 54:202\u2013212","journal-title":"J Biomed Inform"},{"issue":"7","key":"5453_CR27","volume":"7","author":"E Shantsila","year":"2022","unstructured":"Shantsila E, Kozie\u0142-Sio\u0142kowska M, Lip GY (2022) Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 7(7):Cd003186","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"5453_CR28","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.7150\/ijms.34629","volume":"16","author":"K Shimada","year":"2019","unstructured":"Shimada K, Hasegawa S, Nakao S, Mukai R, Sasaoka S, Ueda N et al (2019) Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. Int J Med Sci 16(9):1295\u20131303","journal-title":"Int J Med Sci"},{"issue":"14","key":"5453_CR29","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJMp1302834","volume":"368","author":"MR Southworth","year":"2013","unstructured":"Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368(14):1272\u20131274","journal-title":"N Engl J Med"},{"issue":"1","key":"5453_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12872-025-04510-4","volume":"25","author":"K Sridharan","year":"2025","unstructured":"Sridharan K, Sivaramakrishnan G (2025) Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study. BMC Cardiovasc Dis 25(1):180","journal-title":"BMC Cardiovasc Dis"},{"issue":"1","key":"5453_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10557-020-07110-w","volume":"36","author":"X Sun","year":"2022","unstructured":"Sun X, Ze B, Zhang LJ, BaiMa YZ, Zuo W, Zhao B et al (2022) Hemorrhage risk profiles among different antithrombotic regimens: evidence from a real-world analysis of postmarketing surveillance data. Cardiovasc Drugs Ther 36(1):103\u2013112","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"5453_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ddr.22025","volume":"84","author":"YZ Wang","year":"2023","unstructured":"Wang YZ, Chen J, Pei SQ, Wang C, Han G, Kan LD et al (2023) Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug Dev Res 84(2):326\u2013336","journal-title":"Drug Dev Res"},{"issue":"11","key":"5453_CR33","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1161\/STROKEAHA.124.048243","volume":"55","author":"M Wilson","year":"2024","unstructured":"Wilson M, Incontri D, Vu S, Marchina S, Wang JY, Andreev A et al (2024) Association of anticoagulant use with hemorrhage location and etiology in incident spontaneous intracerebral hemorrhage. Stroke 55(11):2677\u20132684","journal-title":"Stroke"},{"issue":"1","key":"5453_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12872-019-1165-5","volume":"19","author":"J Zhang","year":"2019","unstructured":"Zhang J, Tang J, Cui X, Wang B, Bu M, Bai Y et al (2019) Indirect comparison of novel oral anticoagulants among Asians with non-valvular atrial fibrillation in the real world setting: a network meta-analysis. BMC Cardiovasc Disord 19(1):182","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"5453_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M (2021) Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 18(11):785\u2013802","journal-title":"Nat Rev Cardiol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05453-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:02:54Z","timestamp":1787666574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05453-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5453"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05453-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used de-identified, publicly accessible FAERS data maintained for FDA drug-safety surveillance; institutional review board approval and patient consent were therefore not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}